The mutational EGFR status of a patient facilitated a diagnosis of lung adenocarcinoma metastasis, resulting in targeted treatment with erlotinib or gefitinib (EGFR inhibitor) and consequently disease remission [94]. The gene discussed is EGFR; the disease is lung adenocarcinoma.